Grace Therapeutics (GRCE) Minority Interest (2023 - 2024)
Grace Therapeutics' (GRCE) quarterly Minority Interest came in at $5.9 million in Q2 2024, down 2.39% quarter-over-quarter from $6.0 million in Q1 2024.
Powered by 
Analysis
Grace Therapeutics (GRCE) Minority Interest (2023 - 2024) Analysis & Trends
Grace Therapeutics has disclosed Minority Interest across 2 years of filings, most recently posting $5.9 million for Q2 2024.
- In Q2 2024, Minority Interest changed N/A year-over-year to $5.9 million; the TTM figure through Jun 2024 stood at $5.9 million (changed N/A YoY), while the FY2024 annual figure was $6.0 million, changed N/A from the prior year.
- Minority Interest came in at $5.9 million for Q2 2024 at Grace Therapeutics, down from $6.0 million in the prior quarter.
- In the past five years, Minority Interest ranged from a high of $6.0 million in Q1 2024 to a low of $7670.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Grace Therapeutics | 39.38 Mn | 39.38 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 5.88 Mn |
| Mar 31, 2024 | 6.02 Mn |
| Dec 31, 2023 | 7,670.00 |
| Sep 30, 2023 | 8,500.00 |